Companies /Healthcare

Progyny Inc

NASDAQ: PGNY Healthcare Plans
$27.35
▲ $0.27 (+1.00%) today
Markets closed · 11:24am ET

Q2 2025 Earnings

Reported Aug 7, 2025, 4:07pm ET · SEC source
$0.48
Beat +12.07%
EPS · est. $0.43
$332.9M
Beat +3.99%
Revenue · est. $320.1M
−3.3%
Trailing market
PGNY vs S&P since report
2 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
0+8%+16%+24%Aug 7Aug 8report 4:07pm ETearnings+0.8%+12.4%
0+8%+16%+24%Aug 7Aug 8earnings+0.8%+12.4%
PGNY +12.4%S&P 500 +0.8%
0+8%+16%+24%Aug 7Aug 8report 4:07pm ETearnings+0.9%+12.4%
0+8%+16%+24%Aug 7Aug 8earnings+0.9%+12.4%
PGNY +12.4%NASDAQ +0.9%
−12%−6%0+6%Aug 6Aug 15report 4:07pm ETearnings+1.6%−2.5%
−12%−6%0+6%Aug 6Aug 15earnings+1.6%−2.5%
PGNY −2.5%S&P 500 +1.6%
−12%−6%0+6%Aug 6Aug 15report 4:07pm ETearnings+1.3%−2.5%
−12%−6%0+6%Aug 6Aug 15earnings+1.3%−2.5%
PGNY −2.5%NASDAQ +1.3%
−0.91%
Day of report
−4.81%
Next session
+2.41%
One week
−0.96%
30 days

S&P 500 over the same 30 days: +2.36%.

Did PGNY Beat Earnings? Q2 2025 Results

Progyny posted a strong second quarter, with adjusted EPS of $0.48 clearing the $0.43 consensus estimate by 12.07% and revenue of $332.87 million topping expectations by 3.99%, rising 9.5% year-over-year to mark a record Q2 result. The most material driver was continued client base expansion, as the fertility benefits specialist grew its roster to 542 clients from 463 a year ago while average members climbed to 6.74 million, with underlying revenue growth reaching 18% when excluding a large departed client whose transition agreement expired June 30. Gross margin widened 120 basis points to 23.7%, and operating cash flow of $55.50 million in the quarter helped push first-half cash generation to a record $105.30 million, underpinning a debt-free balance sheet. Management raised full-year 2025 guidance, now projecting revenue of $1.24 billion to $1.27 billion and adjusted EPS of $1.70 to $1.78, though the Q3 outlook of $290 million to $305 million reflects the absence of the departed client's contribution in the second half. Cantor Fitzgerald recently reiterated an Overweight rating on the stock following the results.

Key Takeaways
  • Increase in number of clients from 463 to 542 year-over-year
  • Growth in average covered members to 6,743,000 from 6,409,000
  • Continued increase in pacing of member engagement
  • Gross margin expansion to 23.7% from 22.5%
  • ART cycles grew to 16,938 from 15,562 in Q2 2024
  • Excluding departed large client, underlying revenue growth was 18%

“The strong second quarter results reflect the continued increase in the pacing of member engagement, as members pursued the care and services they need in order to best address their health and family building goals.”

Progyny CEO, on the earnings call

Forward Guidance & Outlook

Progyny raised its full year 2025 guidance: revenue is now projected at $1.235 billion to $1.270 billion (5.8%–8.8% growth; 15.1%–18.5% excluding the departed large client), net income of $52.3M–$58.9M ($0.58–$0.65 per diluted share), and Adjusted EBITDA of $205.5M–$214.5M. For Q3 2025, revenue is projected at $290M–$305M (1.2%–6.4% growth), net income of $9.4M–$12.3M ($0.10–$0.14 per diluted share), and Adjusted EBITDA of $45M–$49M. Guidance reflects no further revenue contribution from the large departed client in H2 2025, variability in member engagement, potential macroeconomic uncertainty impacts, and continued investments in member experience and acquisition integration. Full-year adjusted EPS is guided at $1.70–$1.78.

PGNY YoY Financials

Q2 2025 vs Q2 2024 · SEC filings Q2 2024 Q2 2025
$0$100.0M$200.0M$300.0M$304.1M$332.9MRevenue$68.3M$79.0MGross Profit$20.7M$24.4MOperating Income$16.5M$17.1MNet Income
$0$100.0M$200.0M$300.0MRevenueGross ProfitOperating IncomeNet Income

PGNY Revenue by Segment

Fertility Benefit Services$213.9M+11.0%
Pharmacy Benefit Services$118.9M+8.0%

Figures from SEC filings and company reports. Not investment advice.